ARTV (Artiva Biotherapeutics) Company Book Value

Artiva Biotherapeutics Inc. (ARTV) - corporate logo

Artiva Biotherapeutics, Inc. (ARTV) management focuses on developing cutting-edge cell therapy methods, successfully raising capital for early-stage production. The historical price action shown below correlates with the 0.35 metric. The business model relies on outsourcing drug manufacturing in Asia while retaining exclusive rights to the developments. Transparent cooperation with GC Cell and the top management's experience in bringing NK products to market ensure quality control following the IPO.

Artiva Biotherapeutics, Inc. (ARTV) Book Capitalization: for the period 07/20/2024 - 11/01/2026
Finished products of artivabio.com

To identify fundamental stability drivers, an investor must evaluate the difference between total assets and liabilities, which allows for the real-time tracking of the enterprise's actual asset value. The trend of net balance sheet assets for Artiva Biotherapeutics, Inc. (ARTV) on the GURU.Markets platform confirms the financial resilience of Artiva Biotherapeutics, Inc. (ARTV), reflecting the capitalization of resources required to maintain the closed-loop production cycle of AlloNK cell therapy and to fulfill exclusive contracts with pharmaceutical behemoths.

Competitor analysis

BeiGene Oncology - Total Net Assets|HALO (Halozyme Therapeutics) - Company Net Assets|RVMD (revmed.com) - Company Book Value|AAPG (Ascentage Pharma) - Book Capitalization|Company Net Assets CG Oncology Inc (CGON)|Book Capitalization URGN|Book Capitalization Bicara Corp (BCAX)|Company Book Value Personalis, Inc. PSNL|ERAS: Accounting Capitalization|Delcath Systems - Book Capitalization|Y-mAbs Therapeutics Inc (YMAB) - Company Net Assets|AURA: Book Capitalization|Total Stockholders' Equity Candel Therapeutics, Inc. (CADL)|Company Book Value Accuray Incorporated|SLS: Accounting Value of Company|Company Net Assets ACTU (Actuate Therapeutics)|CTOR (Citius Oncology Inc.) - Accounting Value of Company|Book Capitalization HURA (TuHURA Biosciences)|TARA - Company Net Assets|FATE: Company Net Assets|WHWK - Book Capitalization|tscan.com (TCRX) - Company Book Value|Champions Oncology, Inc. - Accounting Value of Company|XBIT (XBiotech Inc) - Book Capitalization|Total Stockholders' Equity CEL-SCI Corp CVM|Book Capitalization OSTX|Book Capitalization Radiopharm Theranostics Ltd (RADX)|Company Book Value Adlai Nortye ANL|Accounting Value of Company VERU|TPST: Company Net Assets|Xilio Therapeutics, Inc. - Total Net Assets|RENB: Book Capitalization|MURA - Book Valuation of Business|Company Net Assets KAPA|Company Book Value OKUR|Book Capitalization GDTC|Book Capitalization curis.com (CRIS)|Apollomics - Company Net Assets|Accounting Value of Company THAR|Advanced Biomed Corp - Book Capitalization|GNPX: Company Book Value|CLDI: Book Capitalization|SBFM - Book Valuation of Business|Company Book Value Xenetic Biosciences Inc.|Total Stockholders' Equity salariuspharma.com SLRX|Company Net Assets PPBT (Purple Biotech Ltd.)|Total Net Assets AONC|Book Capitalization BGNE (BeOne Medicines)|Accounting Value of Company CKPT|Elevation Oncology, Inc. - Book Capitalization|Total Stockholders' Equity iCAD, Inc.|ikenaoncology.com (IKNA) - Company Book Value|Notable Labs Ltd - Accounting Value of Company|VIRX (Viracta Therapeutics Inc.) - Book Capitalization|Book Capitalization MorphoSys Corporation|Company Book Value NAYA Biosciences (NAYA)|AAPGV: Net Asset Value